Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda, NCC Join Hands on Cancer Drug Research
May 11, 2015
- Takeda to Return Latuda Rights in Europe to Sumitomo Dainippon
May 8, 2015
- Takecab Tops in GP and HP Markets for 3rd Month in a Row in March: Anterio Ranking
May 8, 2015
- Oncolys Initiates PI Trial of Novel Anticancer Drug in Patients with Solid Cancers in the US
May 8, 2015
- US Drug Spending Spikes in 2014 Lifted by Cancer, Hepatitis C Medicines: IMS
May 7, 2015
- PhRMA Member Companies Invest US$51.2 Billion in New Drug R&D in 2014
May 7, 2015
- US Sales of Abilify Rise 2.4% in January-March: Otsuka Holdings
May 7, 2015
- Zeria Cuts FY2014 Forecasts, to Lose 40% of Estimated Profits
May 7, 2015
- Fujifilm Holdings Acquires Cellular Dynamics International through Tender Offer
May 7, 2015
- Nichi-Iko Most Favored Maker of Plavix Generics: Survey
May 1, 2015
- Takeda Agrees to Pay US$2.37 Billion to Settle Actos Suits, Braces for 1st Net Loss
May 1, 2015
- Toho Holdings Names Hiroyuki Kono as Next Chairman
April 30, 2015
- Daiichi Sankyo Cuts FY2014 Forecasts on Write-Off Loss Tied to Zelboraf
April 30, 2015
- Boehringer Japan Pharma Sales Grow 3 Times Faster than Market in 2014
April 30, 2015
- Eliquis Shows Lower Incidence of Adverse Events Including Major Bleeding in PIII Study in Patients with Acute VTE
April 28, 2015
- Lixiana Recommended for European Approval by CHMP: Daiichi Sankyo
April 28, 2015
- Sanofi Files Primaquine for Vivax Malaria, Ovale Malaria in Japan
April 28, 2015
- Novartis Seeks Japan Approval for 2 Malignant Melanoma Drugs Transferred from GSK
April 28, 2015
- Eisai, Nihon Medi-Physics Tie Up for Diagnosis, Treatment of Dementia with Lewy Bodies
April 28, 2015
- Opdivo Gains Positive CHMP Opinion for Advanced Melanoma
April 27, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…